Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...

The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

AbCellera Biologics (NASDAQ:ABCL) used its presentation at the 2026 JPMorgan Healthcare Conference to outline its shift from ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Nvidia and Eli Lilly's AI tie-up shows drug discovery emerging as a new ETF growth theme across semiconductors and health ...

The company is embracing AI integration throughout drug development, aiming to improve efficiency and drive portfolio ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Celltrion reaffirmed its commitment to expanding both its biosimilar and novel drug pipelines as the Korean biopharmaceutical ...

Celltrion outlines a blueprint for innovative drug development built on its antibody expertiseThe company highlights its ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...